NG
NGL Fine Chem Ltd (NGLFINE)
₹2,747.60
Mkt cap
₹1,880 Cr
P/E ratio
29.40
P/B
4.68
Div yield
0.06%
ROE
17.40%
ROCE
18.60%
EPS (TTM)
₹93.46
Book value
₹587
52W range
1,271–3,602
Sector
Healthcare
Price history
Previous close
Incorporated in 1981, NGL Fine-Chem Ltd is a manufacturer and exporter of pharmaceuticals and intermediates for usage in veterinary and human health. [1]
NSE NGLFINEBSE 524774
Health check
Constructive
ValuationFair
ProfitabilityStrong
GrowthHigh
TechnicalsNeutral
52-week range
−23.72% from high₹2,748
₹1,271+116.18% from low₹3,602
Current
₹2,747.60
Prev close
₹2,777.00
Day
−1.06%
Price performance
1D
−0.88%
1W
−9.49%
1M
+4.01%
3M
−9.25%
6M
+10.02%
1Y
+98.09%
YTD
+95.13%
Financials
Revenue, profit & margin
P/E ratio
29.4×
NGLFINE is 14% below the sector median of 34.0×
NGLFINE29.4×
Sector median34.0×
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 80 | 88 | 100 | 91 | 93 | 89 | 95 | 104 | 120 | 128 | 149 | 139 | 159 | |
| YoY Sales growth | +18% | +22% | +33% | +28% | +17% | +1% | -5% | +15% | +29% | +43% | +57% | +34% | +32% | |
| Expenses | 66 | 74 | 84 | 81 | 82 | 84 | 89 | 93 | 103 | 105 | 128 | 116 | 131 | |
| Operating Profit | 14 | 14 | 16 | 9 | 12 | 5 | 6 | 11 | 17 | 22 | 21 | 23 | 28 | |
| OPM % | 17% | 16% | 16% | 10% | 12% | 6% | 7% | 11% | 14% | 18% | 14% | 17% | 18% | |
| Other Income | 3 | 4 | 4 | 6 | 5 | -0 | -1 | 6 | 2 | 5 | 2 | 7 | 1 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |
| Depreciation | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 5 | 5 | 5 | 5 | 7 | |
| Profit before tax | 14 | 14 | 16 | 12 | 13 | 1 | 1 | 12 | 13 | 21 | 18 | 24 | 22 | |
| Tax % | 25% | 30% | 23% | 22% | 26% | -1% | 49% | 22% | 26% | 24% | 24% | 25% | 25% | |
| Net Profit | 10 | 10 | 12 | 9 | 10 | 1 | 1 | 9 | 10 | 16 | 13 | 18 | 16 | |
| EPS in Rs | 16.96 | 16.24 | 19.94 | 14.92 | 15.88 | 2.07 | 0.87 | 14.96 | 15.59 | 25.40 | 21.84 | 29.78 | 26.30 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Results analysis
Shareholding
as of Sep 202672.49%Promoter
Promoters72.49%
FIIs0.04%0.01
DIIs0.00%0.02
Public27.46%0.03
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,880.00 | 36.66 | 4,51,075 | 0.85% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹11,442.00 | 88.89 | 3,03,749 | 0.26% | 1,127 | +63.57% | 3,676 | +35.40% | 21.97% |
| Torrent Pharma. | ₹4,670.00 | 81.82 | 1,77,632 | 0.81% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,424.00 | 97.75 | 1,30,972 | 0.08% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,189.90 | 26.20 | 1,18,693 | 0.08% | 928 | −27.96% | 7,910 | +29.17% | 21.14% |
| Dr Reddy's Labs | ₹1,380.00 | 41.17 | 1,15,267 | 0.58% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,391.80 | 36.21 | 1,12,442 | 0.93% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| NGL Fine Chem | ₹3,041.30 | 29.45 | 1,880 | 0.06% | 16 | +68.74% | 159 | +31.97% | 18.58% |
| Median: 160 Co. | ₹465.83 | 33.99 | 2,012 | 0.08% | 13 | +33.53% | 179 | +20.92% | 14.94% |
Filings
Annual reports15
Concall transcripts46
PPTNov 2026RECNov 2026PPTAug 2026TranscriptMay 2026PPTMay 2026PPTFeb 2026TranscriptNov 2025PPTNov 2025PPTAug 2025TranscriptMay 2025PPTMay 2025PPTFeb 2025TranscriptNov 2024PPTNov 2024PPTAug 2024TranscriptJun 2024PPTJun 2024RECJun 2024PPTMay 2024PPTFeb 2024TranscriptNov 2023TranscriptNov 2023PPTNov 2023RECNov 2023
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 12 Nov - Audio recording of Q2 and H1 FY27 earnings conference call uploaded on November 12, 2026.Announcement under Regulation 30 (LODR)-Investor Presentation 10 NovAnnouncement under Regulation 30 (LODR)-Newspaper Publication 9 NovAnnouncement under Regulation 30 (LODR)-Newspaper Publication 9 NovDisclosure under Regulation 30A of LODR 6 Nov - Board approved Q2 FY26 results and PPAs for 3.10 MW solar, 3.60 MW wind captive power.






